A company committed

to change

Sanjay Kakkar, MD, MSc, MPH is a biotech entrepreneur and executive with over 25 years of experience in multinational, early-stage and high growth enterprises. He has a track record of building innovative companies in the life sciences industries in Europe, Asia and the US and advancing novel technologies for the improvement of human health. Prior to Tranquis, he served as CEO at Peptilogics, Armetheon, and Trigen (which he also co-founded), and was the founder and chairman of Jai Medica. Before becoming a serial entrepreneur, he held R&D roles at Pharmacia (now Pfizer) and Novartis. Sanjay received his medical degree from King’s College, University of London, holds a Master’s degree in healthcare management from Harvard University and a Master’s degree in preventive cardiology from Imperial College.

Frederic Godderis, MSc is a biopharmaceutical R&D leader and entrepreneur with extensive strategic and operational drug development experience. Throughout his career, he has contributed to the development of numerous drugs and established operating models, capabilities, and leadership structures in a variety of large and startup organizational settings. Before joining Tranquis, Frederic served as co-founder and CEO of LARRK Bio Inc. and led R&D Operations, Program Leadership, and Program & Portfolio Management functions at Janssen (Johnson & Johnson), Jazz Pharmaceuticals and Prothena Biosciences. Frederic began his career at Janssen and worked for several J&J entities across Europe and the US. Frederic received his MS from K.U. Leuven, Belgium.

Jonas Hannestad, MD, PhD, has more than 20 years of translational and early clinical development experience. His academic work focused on immuno-neurology, particularly on the effect of systemic inflammation on myeloid cells in the brain. His expertise spans multiple disease areas, including Parkinson’s, Alzheimer’s, and ALS. Previously, he served as SVP of Clinical Development at Alkahest, Medical Director at Denali Therapeutics, and Director of Neuroscience Discovery Medicine at UCB Pharma. Prior to his industry work, Dr. Hannestad led the Clinical Neuroscience Research Unit at Yale School of Medicine. He did postdoctoral work and residency training at Bristol-Myers Squibb, Duke School of Medicine and UCLA Neuropsychiatric Institute. He received his PhD in Cell Biology from the University of Messina, Italy, and his MD from the University of Oviedo, Spain.

Andrew Lam, BS, has over 30 years of experience in pharmaceutical product development and has contributed to the NDA registration and regulatory approvals of multiple products in the US, EU, Japan, and China. Prior to Tranquis, Andrew held senior management positions at Espero, Armetheon, Altheos, Exelixis and ALZA, a Johnson and Johnson company. He advanced discovery compounds in late-stage optimization to IND clinical development and directed chemical development, product scale-up, registration, and global product launch. Andrew was the recipient of the Johnson Medal, the highest scientific award at J&J, for development of Concerta®. Andrew earned his BS degree in Chemical Engineering with high honors from the University of California, Davis.

Enchi Liu, PhD, has more than 20 years of experience in drug development, spanning translational, early, and late development. Her research spans CNS (mood, pain, sleep), neurodegenerative disorders (AD, HD, ALS, PD), and rare diseases (AL and ATTR amyloidosis, LSDs). She is expert in integration of biomarkers into preclinical and development programs. Prior to joining Tranquis, she was PTL for Neurology at Annexon, lead Clinical and Translational Sciences at Escape Bio, PTL at Prothena, and Clinical Biomarker Leader at Janssen for multiple CNS programs. She did postdoctoral research at the University of Arizona and received her PhD from Cornell University.